CA2936952C - Chromene derivatives as cox-2 inhibitors - Google Patents
Chromene derivatives as cox-2 inhibitors Download PDFInfo
- Publication number
- CA2936952C CA2936952C CA2936952A CA2936952A CA2936952C CA 2936952 C CA2936952 C CA 2936952C CA 2936952 A CA2936952 A CA 2936952A CA 2936952 A CA2936952 A CA 2936952A CA 2936952 C CA2936952 C CA 2936952C
- Authority
- CA
- Canada
- Prior art keywords
- chromene
- trifluoromethyl
- nitrooxy
- cancer
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927344P | 2014-01-14 | 2014-01-14 | |
| US61/927,344 | 2014-01-14 | ||
| PCT/US2015/011454 WO2015109011A1 (en) | 2014-01-14 | 2015-01-14 | No-releasing nitrooxy-chromene conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2936952A1 CA2936952A1 (en) | 2015-07-23 |
| CA2936952C true CA2936952C (en) | 2023-01-24 |
Family
ID=53543408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2936952A Active CA2936952C (en) | 2014-01-14 | 2015-01-14 | Chromene derivatives as cox-2 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10266511B2 (https=) |
| EP (1) | EP3094333B1 (https=) |
| CN (1) | CN106102747A (https=) |
| AU (1) | AU2015206528B2 (https=) |
| BR (1) | BR112016016386B1 (https=) |
| CA (1) | CA2936952C (https=) |
| ES (1) | ES2836374T3 (https=) |
| IL (1) | IL246794B (https=) |
| MX (1) | MX369245B (https=) |
| WO (2) | WO2015109011A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105585547A (zh) * | 2016-03-09 | 2016-05-18 | 中国科学院广州生物医药与健康研究院 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101563A1 (en) | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
| ITMI20021391A1 (it) | 2002-06-25 | 2003-12-29 | Nicox Sa | Nitroderivati di inibitori della cicloossigenasi-2 |
| EP1562914A1 (en) | 2002-10-22 | 2005-08-17 | Merck Frosst Canada & Co. | Nitric oxide releasing selective cyclooxygenase-2 inhibitors |
| EP1603933A2 (en) * | 2003-03-13 | 2005-12-14 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
| US7259266B2 (en) | 2003-03-31 | 2007-08-21 | Pharmacia Corporation | Benzopyran compounds useful for treating inflammatory conditions |
| US20050148627A1 (en) | 2003-03-31 | 2005-07-07 | Jeffery Carter | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| EP1692107A4 (en) * | 2003-12-10 | 2008-10-29 | Nitromed Inc | NITROGEN OXIDE-RELATED PYRUVATE COMPOUNDS, COMPOSITIONS AND USE METHOD |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
| WO2009009776A2 (en) | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Patient selection and therapeutic methods using markers of prostaglandin metabolism |
| CN103012350B (zh) * | 2012-12-07 | 2015-02-04 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
-
2015
- 2015-01-14 WO PCT/US2015/011454 patent/WO2015109011A1/en not_active Ceased
- 2015-01-14 US US15/111,767 patent/US10266511B2/en active Active
- 2015-01-14 CN CN201580012500.XA patent/CN106102747A/zh active Pending
- 2015-01-14 WO PCT/US2015/011456 patent/WO2015109013A1/en not_active Ceased
- 2015-01-14 EP EP15737116.2A patent/EP3094333B1/en active Active
- 2015-01-14 ES ES15737116T patent/ES2836374T3/es active Active
- 2015-01-14 BR BR112016016386-9A patent/BR112016016386B1/pt active IP Right Grant
- 2015-01-14 AU AU2015206528A patent/AU2015206528B2/en active Active
- 2015-01-14 CA CA2936952A patent/CA2936952C/en active Active
- 2015-01-14 MX MX2016009222A patent/MX369245B/es active IP Right Grant
-
2016
- 2016-07-14 IL IL246794A patent/IL246794B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3094333A4 (en) | 2017-09-06 |
| MX2016009222A (es) | 2017-03-06 |
| EP3094333B1 (en) | 2020-10-14 |
| CN106102747A (zh) | 2016-11-09 |
| US20160340330A1 (en) | 2016-11-24 |
| WO2015109013A1 (en) | 2015-07-23 |
| CA2936952A1 (en) | 2015-07-23 |
| ES2836374T3 (es) | 2021-06-24 |
| BR112016016386B1 (pt) | 2023-02-23 |
| BR112016016386A2 (https=) | 2017-08-08 |
| AU2015206528B2 (en) | 2019-04-18 |
| MX369245B (es) | 2019-11-01 |
| WO2015109011A1 (en) | 2015-07-23 |
| IL246794A0 (en) | 2016-08-31 |
| IL246794B (en) | 2020-04-30 |
| EP3094333A1 (en) | 2016-11-23 |
| US10266511B2 (en) | 2019-04-23 |
| AU2015206528A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3445749B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| WO2021027911A1 (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| CN106660974B (zh) | 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| TWI798470B (zh) | 作為神經激肽－１受體拮抗劑的化合物及其用途 | |
| EP2594555A1 (en) | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | |
| CN117597341A (zh) | 磺酰胺衍生物、其制备方法及其在医药上的应用 | |
| CN114341162A (zh) | 作为治疗剂的细胞毒素的肽缀合物 | |
| EP3210969B1 (en) | Kcnq2-5 channel activator | |
| CN105008343A (zh) | 作为选择性雌激素受体降解剂的苯并噻吩衍生物及其组合物 | |
| ES2371932T3 (es) | Derivados de pirazina como moduladores de los canales de sodio para el tratamiento del dolor. | |
| WO2017101791A1 (zh) | 化合物及其在制备药物中的用途 | |
| JP2025511974A (ja) | がんの治療のためのラクテート／ＡＴＰ産生阻害剤としてのＮ－（３－（ベンゾ［ｂ］チオフェン－２－カルボキシアミド）－フェニル）－２，３－ジヒドロベンゾ［ｂ］［１，４］ジオキシン－６－カルボキシアミド誘導体及び関連化合物 | |
| US20150197500A1 (en) | No-releasing guanidine-chromene conjugates | |
| WO2015109014A1 (en) | No-releasing nonoate(oxygen-bound)chromene conjugates | |
| CA2936952C (en) | Chromene derivatives as cox-2 inhibitors | |
| US9044464B2 (en) | No-releasing guanidine-coxib anti-cancer agents | |
| CA3258147A1 (en) | INTERFERON GENE STIMULATOR AGONIST COMPOUNDS | |
| CN116332904A (zh) | Hpk1抑制剂及其在医药上的应用 | |
| JP2023531020A (ja) | スルホン誘導体 | |
| HK1226644A1 (en) | No-releasing nitrooxy-chromene conjugates | |
| HK40130127A (zh) | 用於治疗癌症及炎性疾病的咪唑幷[1，2-a]吡啶化合物及其制备所述化合物的方法 | |
| KR20260029377A (ko) | 암 및 염증성 질환 치료에 사용하기 위한 이미다조[1,2-α]피리딘 화합물 및 그 화합물의 제조 방법 | |
| US20150197494A1 (en) | No-releasing nitrooxy-methylene-linked-coxib conjugates | |
| WO2025036382A1 (zh) | 一种磺酰胺类化合物、其制备方法及用途 | |
| WO2024109917A1 (zh) | 一种三唑衍生物及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200110 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250110 |